Supriya Lifescience: Further Update on Judicial Proceedings – Intimation
Supriya Lifescience (SUPRIYA) filed a disclosure titled "Further Update on Judicial Proceedings – Intimation". The company is valued at about ₹6,932 crore.
What happened
Supriya Lifescience (SUPRIYA) filed a disclosure with the exchanges on 8 October 2026 at 04:48 PM titled "Further Update on Judicial Proceedings – Intimation".
Company snapshot
Supriya Lifescience is a small-cap company in the Healthcare sector, with a market value of about ₹6,932 crore.
The stock last traded at ₹861.4, against a 52-week range of ₹545.5–₹1,085 (20.6% below the high).
Before this filing the shares had moved −2.2% over the month and +1.6% over three months. Average daily turnover over the last 20 sessions was about ₹27.74 crore.
Promoters held 68.30% at the end of Q1 FY27. Foreign institutions owned 6.19% and domestic institutions 5.30%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 145 | 34.8 | 4.32 |
| Q2 FY26 | 200 | 50.4 | 6.27 |
| Q3 FY26 | 206 | 49.7 | 6.17 |
| Q4 FY26 | 277 | 74.2 | 9.22 |
| Q1 FY27 | 190 | 24 | 2.99 |
What history shows
BCEIE has no earlier litigation filing from this company on record since May 2026.
Across 17 similar disclosures by other Healthcare companies, shares moved −0.5% on average the next day and +0.3% over five days; 35% of them rose the next day.
Market-wide, 555 litigation filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 36% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.